NEURIZON THERAPEUTICS ORD
Neurizon Therapeutics Gains Ethics Approval for NUZ-001 Oral Liquid Phase 1 Study
Neurizon gains ethics approval for NUZ-001 oral liquid Phase 1 ALS study in Australia; trial slated to start Q3 2026 and finish Q4 2026.
Neurizon Therapeutics Secures Over $44M in Funding to Advance HEALEY ALS Trial
Neurizon Therapeutics (ASX: NUZ) has successfully raised over $44 million AUD through a multi-pronged capital raise, securing funding to advance its lead drug candidate NUZ-001 through the **H
Neurizon Therapeutics confirms potential of NUZ-001 as platform therapy for ALS and Huntington’s disease
Clinical-stage biotechnology company Neurizon Therapeutics (ASX: NUZ) has continued its success in proving the versatility of lead drug candidate NUZ-001. New studies have confirmed NUZ-001’s potential to provide significant blood–brain barrier penetration. Rodent preclinical pharmacokinetic (PK) data have found that NUZ-001 and its major active metabolite NUZ-001 sulfone effectively cross the blood–brain barrier (BBB) and […]
Neurizon Therapeutics reports positive study results on human brain model by neuroprotective candidate NUZ-001
Neurizon Therapeutics (ASX: NUZ) has reported positive results from an independent study into the effects of neuroprotective candidate NUZ-001 on a 3D human brain model developed by Tessara Therapeutics. The results showed that NUZ-001 and NUZ-001 sulfone (the major active metabolite) exhibited strong safety characteristics in Tessara’s ArtiBrain model over a three-day period at doses […]
